“Panacea Biotec ensures limited availability of life saving drug Cilamin 250 capsule (D- Penicillamine IP 250 mg),” the company said in a filing to the Bombay Stock Exchange on September 29, 2016.
The drug is used for treatment of Wilson’s disease, rheumatoid arthritis and other conditions.
“The temporary shortage is due to sudden disruption of supplies of raw material by qualified supplier beyond the control of the company. Since then company has been working tirelessly with alternate suppliers for supply of this raw material. Due to continuous efforts we have resumed limited production of Cilamin 250 and have released limited quantities in the market from September 26, 2016,” the company said in a statement.
However, it has started the supply of new batches with limited quantities of Cilamin 250 from September 26, 2016 from its manufacturing facility in Baddi, Himachal Pradesh under Good Manufacturing Practices, the company added.
The company further said that, it will continue to work closely with existing and potential new raw material suppliers in China and India for access to the raw material in an accelerated manner.
Meanwhile, shares of the company closed at Rs 110.55 apiece, down 5.47 per cent, from previous close on BSE.